Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Veracyte, Inc. (Nasdaq: VCYT) SEC filings, offering a detailed view into the company’s financial reporting, governance decisions, and key disclosures. Veracyte is a global cancer diagnostics and genomic testing company whose filings reflect its activities in developing and commercializing tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, as well as research platforms like Afirma GRID and Decipher GRID.
Investors can review Veracyte’s periodic reports on Forms 10-K and 10-Q for information about revenue composition, testing volumes, cost structure, and risk factors. Current reports on Form 8-K capture specific events, such as the release of quarterly financial results or shareholder votes. For example, recent 8-K filings describe quarterly earnings press releases and the approval of amendments to the company’s equity incentive plan, along with voting outcomes at the annual meeting of stockholders.
These filings also discuss Veracyte’s use of non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA margin, and explain which items are excluded from these metrics, such as amortization of acquired intangible assets, acquisition-related expenses, stock-based compensation, and certain restructuring costs. This context helps readers understand how management evaluates the company’s performance relative to GAAP results.
On Stock Titan, Veracyte filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight the main points of lengthy documents, helping users quickly identify key topics such as revenue trends, test portfolio updates, equity plan changes, and shareholder voting results. Users can also monitor forms that may relate to insider activity and executive compensation through the company’s proxy and related disclosures, using the AI tools to navigate complex regulatory language more efficiently.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported an automatic share disposition related to tax withholding. On March 2, 2026, 7,517 shares of common stock were withheld at a price of $36.01 per share to cover taxes on vesting restricted stock units, leaving him with 112,840 directly owned shares. The filing specifies this did not represent an open-market sale.
Veracyte, Inc. executive Phillip G. Febbo reported two stock transactions on March 2, 2026. The company withheld 6,035 shares of common stock at $36.01 per share to cover his tax obligations from vesting restricted stock units, which is not a market sale. He also completed an open-market sale of 13,425 shares at a weighted average price of $36.1586 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 117,346 shares of Veracyte common stock.
VERACYTE, INC. Chief Executive Officer Marc Stapley reported a tax-related share disposition. On March 2, 2026, 19,455 shares of common stock were withheld to satisfy tax obligations tied to vesting restricted stock units at a reference price of $36.01 per share. Following this withholding, he directly owns 403,077 shares of Veracyte common stock. The footnote clarifies this was not an open-market sale but a tax-withholding transaction.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported equity-related transactions in company common stock. He acquired 47,149 shares on February 26, 2026 from vesting of performance-based restricted stock units after the board certified achievement of performance goals. On the same date, 8,905 shares were disposed at $38.75 per share to cover tax withholding obligations tied to this vesting, which the disclosure states does not represent a sale. Following these transactions, he directly owned 120,357 shares of Veracyte common stock.
Veracyte, Inc. Chief Executive Officer Marc Stapley reported equity compensation activity involving the company’s common stock. He acquired 139,074 shares on February 26, 2026 through the vesting of performance-based restricted stock units after the board certified achievement of required performance goals. Of these units, 70,239 PSUs vested immediately, while 68,835 PSUs are scheduled to vest on December 2, 2026, contingent on his continued service. To cover tax withholding obligations from this vesting, 35,841 shares were withheld at $38.75 per share, which the filing states does not represent an open-market sale. Following these transactions, Stapley directly held 422,532 shares of Veracyte common stock.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported equity compensation activity involving the company’s common stock. On February 26, 2026, she acquired 59,324 shares at no cost upon vesting of performance-based restricted stock units after the board certified achievement of performance goals. On the same date, 12,049 shares were withheld at a price of $38.75 per share to cover tax obligations related to this vesting, which the company notes does not represent a sale. Following these transactions, Chambers directly owned 156,771 shares of Veracyte common stock.
VERACYTE, INC. reported an equity award transaction for Chief Scientific & Med Officer Phillip G. Febbo. On February 26, 2026, he acquired 71,806 shares of common stock at $0.00 per share through the vesting of performance-based restricted stock units. According to the award terms, 47,863 PSUs vested on that date and 23,943 additional PSUs are scheduled to vest on December 2, 2026, subject to continued service. To cover tax withholding from the vesting, 24,486 shares were withheld at $38.75 per share, a disposition that did not involve an open-market sale. Following these transactions, he directly owned 136,806 common shares.
Veracyte, Inc. reported that SVP and General Counsel Annie McGuire acquired 50,999 shares of common stock through the vesting of performance-based restricted stock units on February 26, 2026. According to the filing, 21,071 PSUs vested on that date, with 29,928 additional PSUs scheduled to vest on December 2, 2026, subject to her continued service.
The filing also notes that 10,867 shares were withheld to cover tax obligations related to the PSU vesting, which is characterized as a tax-withholding disposition rather than an open-market sale. After these transactions, McGuire directly owned 108,266 shares of Veracyte common stock, including 374 shares purchased earlier under the company’s employee stock purchase plan.
Veracyte, Inc. outlines its role as a global cancer diagnostics company focused on high‑value molecular tests that help personalize treatment decisions. The business centers on laboratory developed tests in the U.S. and in vitro diagnostic kits internationally, with major revenue from Decipher Prostate and Afirma.
The company is investing in growth drivers including its TrueMRD minimal residual disease platform, expansion of Prosigna breast cancer testing as a U.S. lab-developed test and as an IVD globally, and the Percepta Nasal Swab test for lung nodule assessment. Its Veracyte Diagnostics Platform combines whole‑transcriptome and whole‑genome technologies, AI, and extensive evidence generation to secure reimbursement and guideline inclusion.
Veracyte details broad Medicare and commercial coverage for key assays, notes that Medicare fee‑for‑service represented 34% of 2025 testing revenue while private payers contributed 47%, and explains complex U.S., EU, UK and data‑privacy regulatory frameworks governing its labs, tests, and patient information.